EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Targeting factor XIIa for therapeutic interference with hereditary angioedema

Danny M Cohn, Thomas Renné iD

Journal of Internal Medicine · 2024-10 · 296 (4) · 311-326

DOI: 10.1111/joim.20008 ↗

At a glance

Übersichtsarbeit in Journal of Internal Medicine, published online on 2024-09-17. Written by Danny M Cohn and 1 co-authors. Institution: University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Amsterdam, The Netherlands. Major MEDLINE topics: Angioedemas, Hereditary, Factor XIIa. Cited 20 times so far (Crossref); 129 references. The full text is freely available (open access, CC BY 4.0). Funded by: CSL Behring.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Hereditary angioedema (HAE) is a rare, potentially life‐threatening genetic disorder characterized by recurrent attacks of swelling. Local vasodilation and vascular leakage are stimulated by the vasoactive peptide bradykinin, which is excessively produced due to dysregulation of the activated factor XII (FXIIa)‐driven kallikrein–kinin system. There is a need for novel treatments for HAE that provide greater efficacy, improved quality of life, minimal adverse effects, and reduced treatment burden over current first‐line therapies. FXIIa is emerging as an attractive therapeutic target for interference with HAE attacks. In this review, we draw on preclinical, experimental animal, and in vitro studies, providing an overview on targeting FXIIa as the basis for pharmacologic interference in HAE. We highlight that there is a range of FXIIa inhibitors in development for different therapeutic areas. Of these, garadacimab, an FXIIa‐targeted inhibitory monoclonal antibody, is the most advanced and has shown potential as a novel long‐term prophylactic treatment for patients with HAE in clinical trials. The evidence from these trials is summarized and discussed, and we propose areas for future research where targeting FXIIa may have therapeutic potential beyond HAE.

Subjects

MeSH terms (MEDLINE)

Angioedemas, HereditaryFactor XIIaHumansAnimalsAntibodies, Monoclonal, Humanized

Author keywords

angioedemabradykinincapillary permeabilitycoagulation factor XIIgaradacimabkallikrein–kinin systemthrombo‐inflammation

Substances

Factor XIIaAntibodies, Monoclonal, Humanized

Authors and institutions

  • University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Amsterdam, The Netherlands.
  • University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical Center, Mainz, Germany.

ORCID profiles: Thomas Renné

Funding

  • CSL Behring

Cite

APA

Cohn, D. M., & Renné, T. (2024). Targeting factor XIIa for therapeutic interference with hereditary angioedema. Journal of Internal Medicine, 296(4), 311-326. https://doi.org/10.1111/joim.20008

Vancouver

Cohn DM, Renné T. Targeting factor XIIa for therapeutic interference with hereditary angioedema. Journal of Internal Medicine. 2024;296(4):311-326. doi:10.1111/joim.20008

BibTeX
@article{Cohn2024,
  author = {Cohn, Danny M and Renné, Thomas},
  title = {Targeting factor XIIa for therapeutic interference with hereditary angioedema},
  journal = {Journal of Internal Medicine},
  year = {2024},
  volume = {296},
  number = {4},
  pages = {311--326},
  doi = {10.1111/joim.20008}
}
Start for free →